Agnieszka Witkiewicz

Roswell Park Team Reports New Insights on Treatment of Metastatic Breast Cancer

Findings point to features of therapeutic response and potential biomarkers

  • Clinical trial assesses molecular determinants of response to CDK4/6 inhibitor
  • Changes in cell cycle, estrogen receptor signaling occurred during treatment
  • Hormonal signaling, tumor proliferation status noted as potential biomarkers

BUFFALO, N.Y. — Initial results from an in-progress Roswell Park Comprehensive Cancer Center clinical trial offer important insights into hormone receptor-positive and HER2-negative (HR+/HER2−) metastatic breast cancer and patient response to CDK4/6 inhibitors. This study, newly published in NPJ Precision Oncology, identifies pathological and biological features associated with therapeutic response in these patients — suggesting possible treatment strategies for this common breast cancer subtype.